Drugs / DW5421A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07444762 | Apr → Oct 2025 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW5421A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444762 ↗ |
| Route | Oral | “administered orally” NCT07444762 ↗ |